Cargando…
Incidence of type 2 diabetes in familial combined hyperlipidemia
OBJECTIVE: Familial combined hyperlipidemia (FCHL) is common among survivors of a premature myocardial infarction. FCHL patients are characterized by visceral obesity, fatty liver, and insulin resistance. The aim of the present study was to determine the incidence and determinants of type 2 diabetes...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103854/ https://www.ncbi.nlm.nih.gov/pubmed/32193201 http://dx.doi.org/10.1136/bmjdrc-2019-001107 |
_version_ | 1783512125975560192 |
---|---|
author | Brouwers, Martijn C G J de Graaf, Jacqueline Simons, Nynke Meex, Steven ten Doeschate, Sophie van Heertum, Shadana Heidemann, Britt Luijten, Jim de Boer, Douwe Schaper, Nicolaas Stehouwer, Coen D A van Greevenbroek, Marleen M J |
author_facet | Brouwers, Martijn C G J de Graaf, Jacqueline Simons, Nynke Meex, Steven ten Doeschate, Sophie van Heertum, Shadana Heidemann, Britt Luijten, Jim de Boer, Douwe Schaper, Nicolaas Stehouwer, Coen D A van Greevenbroek, Marleen M J |
author_sort | Brouwers, Martijn C G J |
collection | PubMed |
description | OBJECTIVE: Familial combined hyperlipidemia (FCHL) is common among survivors of a premature myocardial infarction. FCHL patients are characterized by visceral obesity, fatty liver, and insulin resistance. The aim of the present study was to determine the incidence and determinants of type 2 diabetes (T2D) in a longitudinal cohort of FCHL pedigrees. RESEARCH DESIGN AND METHODS: FCHL patients, their unaffected relatives and spouses included in our baseline cohort in 1998–2005 (n=596) were re-invited to determine the incidence of self-reported T2D (that was confirmed by medical records), used as the primary outcome measure. The Fatty Liver Index (FLI) and Homeostasis Model Assessment Insulin Resistance (HOMA2-IR) were used as markers of fatty liver and insulin resistance, respectively. A subset of the original cohort underwent ultrasound of the liver, and subcutaneous and visceral fat in 2002–2005 (n=275; ‘ultrasound subcohort’). RESULTS: Follow-up data (median: 15 years) was acquired for 76%. The incidence rate of T2D was significantly higher in FCHL patients compared with spouses (19.2 per 1000 person-years vs 2.8 per 1000 person-years; HR : 6.3, 95% CI: 2.4 to 16.8), whereas no differences were observed between unaffected relatives and spouses (HR: 0.9, 95% CI: 0.3 to 2.6). Cox’s proportional hazard regression analyses showed that baseline HOMA2-IR and FLI≥60, but not waist circumference, BMI, or the FCHL affected state, were independently associated with incident T2D. Similar results were obtained in the ultrasound subcohort (median follow-up: 11 years), in which baseline HOMA2-IR and fatty liver (assessed by ultrasound) were independently associated with incident T2D. CONCLUSION: This study further corroborates the suggestion that the liver plays a central role in the pathogenesis of cardiometabolic complications in FCHL. It supports periodical screening for T2D in this high-risk population. |
format | Online Article Text |
id | pubmed-7103854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-71038542020-03-31 Incidence of type 2 diabetes in familial combined hyperlipidemia Brouwers, Martijn C G J de Graaf, Jacqueline Simons, Nynke Meex, Steven ten Doeschate, Sophie van Heertum, Shadana Heidemann, Britt Luijten, Jim de Boer, Douwe Schaper, Nicolaas Stehouwer, Coen D A van Greevenbroek, Marleen M J BMJ Open Diabetes Res Care Cardiovascular and Metabolic Risk OBJECTIVE: Familial combined hyperlipidemia (FCHL) is common among survivors of a premature myocardial infarction. FCHL patients are characterized by visceral obesity, fatty liver, and insulin resistance. The aim of the present study was to determine the incidence and determinants of type 2 diabetes (T2D) in a longitudinal cohort of FCHL pedigrees. RESEARCH DESIGN AND METHODS: FCHL patients, their unaffected relatives and spouses included in our baseline cohort in 1998–2005 (n=596) were re-invited to determine the incidence of self-reported T2D (that was confirmed by medical records), used as the primary outcome measure. The Fatty Liver Index (FLI) and Homeostasis Model Assessment Insulin Resistance (HOMA2-IR) were used as markers of fatty liver and insulin resistance, respectively. A subset of the original cohort underwent ultrasound of the liver, and subcutaneous and visceral fat in 2002–2005 (n=275; ‘ultrasound subcohort’). RESULTS: Follow-up data (median: 15 years) was acquired for 76%. The incidence rate of T2D was significantly higher in FCHL patients compared with spouses (19.2 per 1000 person-years vs 2.8 per 1000 person-years; HR : 6.3, 95% CI: 2.4 to 16.8), whereas no differences were observed between unaffected relatives and spouses (HR: 0.9, 95% CI: 0.3 to 2.6). Cox’s proportional hazard regression analyses showed that baseline HOMA2-IR and FLI≥60, but not waist circumference, BMI, or the FCHL affected state, were independently associated with incident T2D. Similar results were obtained in the ultrasound subcohort (median follow-up: 11 years), in which baseline HOMA2-IR and fatty liver (assessed by ultrasound) were independently associated with incident T2D. CONCLUSION: This study further corroborates the suggestion that the liver plays a central role in the pathogenesis of cardiometabolic complications in FCHL. It supports periodical screening for T2D in this high-risk population. BMJ Publishing Group 2020-03-18 /pmc/articles/PMC7103854/ /pubmed/32193201 http://dx.doi.org/10.1136/bmjdrc-2019-001107 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Cardiovascular and Metabolic Risk Brouwers, Martijn C G J de Graaf, Jacqueline Simons, Nynke Meex, Steven ten Doeschate, Sophie van Heertum, Shadana Heidemann, Britt Luijten, Jim de Boer, Douwe Schaper, Nicolaas Stehouwer, Coen D A van Greevenbroek, Marleen M J Incidence of type 2 diabetes in familial combined hyperlipidemia |
title | Incidence of type 2 diabetes in familial combined hyperlipidemia |
title_full | Incidence of type 2 diabetes in familial combined hyperlipidemia |
title_fullStr | Incidence of type 2 diabetes in familial combined hyperlipidemia |
title_full_unstemmed | Incidence of type 2 diabetes in familial combined hyperlipidemia |
title_short | Incidence of type 2 diabetes in familial combined hyperlipidemia |
title_sort | incidence of type 2 diabetes in familial combined hyperlipidemia |
topic | Cardiovascular and Metabolic Risk |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103854/ https://www.ncbi.nlm.nih.gov/pubmed/32193201 http://dx.doi.org/10.1136/bmjdrc-2019-001107 |
work_keys_str_mv | AT brouwersmartijncgj incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT degraafjacqueline incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT simonsnynke incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT meexsteven incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT tendoeschatesophie incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT vanheertumshadana incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT heidemannbritt incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT luijtenjim incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT deboerdouwe incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT schapernicolaas incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT stehouwercoenda incidenceoftype2diabetesinfamilialcombinedhyperlipidemia AT vangreevenbroekmarleenmj incidenceoftype2diabetesinfamilialcombinedhyperlipidemia |